Tycel Phillips, MD

Articles

Dr Phillips on the Evolution of BTK Inhibitors in MCL

July 3rd 2024

Tycel Phillips, MD, discusses the evolution of treatment with BTK inhibitors for patients with mantle cell lymphoma.

Dr Phillips on the Safety and Efficacy of Glofitamab in Relapsed/Refractory MCL

June 6th 2024

Tycel Phillips, MD, MPH, discusses updated efficacy and safety data with glofitamab for the treatment of relapsed/refractory mantle cell lymphoma.

Dr Phillips on Ongoing Research in High-Risk MCL

March 28th 2024

Tycel Phillips, MD, MPH, discusses ongoing trials for patients with high-risk mantle cell lymphoma.

Dr Phillips on Efforts to Clarify and Refine Management Approaches in Relapsed/Refractory MCL

March 7th 2024

Tycel Phillips, MD, discusses efforts to clarify and refine the treatment paradigm of patients with mantle cell lymphoma.

Dr Phillips on Unmet Needs in Patients With Relapsed/Refractory MCL

March 5th 2024

Tycel Phillips, MD, discusses unmet needs for patients with relapsed/refractory mantle cell lymphoma.

Dr Phillips on the Treatment Landscape for Patients With MCL

March 1st 2024

Tycel Phillips, MD, discusses the landscape of treatment for patients with mantle cell.

Dr Phillips on Ongoing Research to Address Unmet Needs in Patients With High-Risk MCL

January 17th 2024

Tycel Phillips, MD, discusses the potential advantages of treating patients with relapsed/refractory mantle cell lymphoma in the phase 3 GLOBRYTE trial.

Dr Phillips on the Evolving Treatment Landscape in MCL

October 4th 2023

Tycel Phillips, MD, discusses current and emerging therapeutic treatment strategies for patients with mantle cell lymphoma.

Dr Phillips on the Evaluation of Frontline Treatment With Acalabrutinib Plus BR in MCL

August 31st 2023

Tycel Phillips, MD, MPH, discusses the ongoing phase 3 ECHO trial of acalabrutinib plus bendamustine and rituximab in the front line for patients with mantle cell lymphoma.

Dr Phillips on the Preliminary Efficacy of Acalabrutinib Plus BR in MCL

June 20th 2023

Tycel Phillips, MD, MPH, discusses the updated safety profile and clinical activity seen with the addition of acalabrutinib to bendamustine and rituximab in patients with mantle cell lymphoma.

Dr Phillips on the Investigation of Acalabrutinib/Benendamustine/Rituximab in MCL

June 7th 2023

Tycel Phillips, MD, MPH, discusses the safety and efficacy of acalabrutinib plus bendamustine and rituximab from a phase 1 trial in patients with treatment-naive and relapsed/refractory mantle cell lymphoma.

Dr Phillips on the Implications of the FDA Approval of Pirtobrutinib in R/R Mantle Cell Lymphoma

May 23rd 2023

Tycel Phillips, MD, MPH, discusses the implications of the FDA approval of pirtobrutinib in patients with relapsed/refractory mantle cell lymphoma.

Dr Phillips on Treatment After Progression on a BTK Inhibitor in MCL

May 22nd 2023

Tycel Phillips, MD, MPH, discusses treatment options for patients with relapsed/refractory mantle cell lymphoma who have progressed on covalent BTK inhibitors.

Dr Phillips on the FDA Approval of Epcoritamab in R/R DLBCL

May 19th 2023

Tycel Phillips, MD, discusses the significance of the FDA approval of the bispecific antibody epcoritamab in patients with relapsed/refractory diffuse large B-cell lymphoma.

Dr. Phillips on the Early Implications of Glofitamab Monotherapy in R/R MCL

February 13th 2023

Tycel Phillips, MD, MPH, discusses the key implications of investigating glofitamab monotherapy in patients with relapsed/refractory mantle cell lymphoma.

Dr. Phillips on the FDA Approval of Pirtobrutinib in MCL

January 27th 2023

Tycel Phillips, MD, discusses the significance of the FDA approval of pirtobrutinib in mantle cell lymphoma.

Dr Phillips on Glofitamab Monotherapy in Relapsed/Refractory MCL

December 11th 2022

Tycel Phillips, MD, MPH, discusses the investigation of glofitamab monotherapy in relapsed/refractory mantle cell lymphoma.